Match-making for posaconazole through systems thinking
- Fügi, Matthias A. Swiss Tropical and Public Health Institute, Basel, Switzerland - University of Basel, Switzerland
- Kaiser, Marcel Swiss Tropical and Public Health Institute, Basel, Switzerland - University of Basel, Switzerland
- Tanner, Marcel Swiss Tropical and Public Health Institute, Basel, Switzerland - University of Basel, Switzerland
- Schneiter, Roger University of Fribourg, Switzerland
- Mäser, Pascal Swiss Tropical and Public Health Institute, Basel, Switzerland - University of Basel, Switzerland
- Guan, Xue Li Swiss Tropical and Public Health Institute, Basel, Switzerland - University of Basel, Switzerland
-
05.12.2014
Published in:
- Trends in Parasitology. - 2015, vol. 31, no. 2, p. 46–51
English
Currently available drugs for Chagas’ disease are limited by toxicity and low efficacy in the chronic stage. Posaconazole, the most advanced new anti-chagasic drug candidate, did not fully confirm its initial potential in a Phase II clinical trial for chronic Chagas’ disease. Given that posaconazole is highly active against Trypanosoma cruzi in vitro, and was very well tolerated in clinical trials, it should not be abandoned. Rather, a combination therapy may provide a highly promising outlook. Systems-scale approaches facilitate the hunt for a combination partner for posaconazole, which acts by blocking sterol biosynthesis. Mounting evidence suggests the functional interactions between sterols and sphingolipids in vivo. Here, we propose combining sterol and sphingolipid biosynthesis inhibitors to advance drug development in Chagas’ disease.
- Faculty
- Faculté des sciences et de médecine
- Department
- Département de Biologie
- Language
-
- English
- Classification
- Biological sciences
- License
- License undefined
- Identifiers
-
- RERO DOC 257102
- DOI 10.1016/j.pt.2014.11.004
- Persistent URL
- https://folia.unifr.ch/unifr/documents/304434
Statistics
Document views: 16
File downloads:
- sch_mmp.pdf: 43